Atlas Trials

Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study

Clinical trial NCT04536558 · UNKNOWN

Trial details

NCT number
NCT04536558
Sponsor
Sun Yat-sen University
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy
Start date
2020-10-01
Primary completion
2021-02-01
Enrollment
352

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.